Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Biotechnology Startup Investors in Switzerland in September 2025

Last updated: Sep 2025 A list of 50 angel investors and VC (Venture Capital) funds that invest in Biotechnology startups based in Switzerland. We rank investors based on the number of investments they made in Biotechnology companies from Switzerland. We update this investor list every month.

Top 50 Biotechnology Startup Investors in Switzerland in September 2025

Investor	Biotechnology Switzerland investments
Zürcher Kantonal Bank	29
Foundation for Innovation and Technology (FIT)	24
BioMedPartners	20
Verve Ventures	16
VI Partners	14
Eclosion SA	11
Schroder Adveq	10
redalpine	9
Novartis Venture Fund	9
EQT Life Sciences	9
M Ventures	9
Sofinnova Partners	9
Versant Ventures	8
GoBeyond	7
HTGF (High-Tech Gruenderfonds)	7
Novo Holdings	7
Kinled Holding	7
Index Ventures	6
Bernina BioInvest	6
Omega Funds	5
Lichtsteiner Foundation	5
4FO Ventures	5
Swisscom Ventures	5
Pureos Bioventures	5
Fongit Seed Invest	4
Penny Schiffer	4
New Enterprise Associates	4
Endeavour Vision	4
BB Biotech Ventures	4
Gilde Healthcare	4
Neomed Management	4
OrbiMed	4
Aravis Ventures	4
Founderful	4
SICTIC	4
Aargauische Kantonalbank	4
Initiative Capital Romandie	3
Polytech Ventures	3
Wille Finance	3
Kickfund	3
b2venture	3
Broadview Ventures	3
Pfizer Venture Investments	3
Boehringer Ingelheim Venture Fund	3
BlueOcean Ventures	3
EVA Basel	3
Sunstone Life Science Ventures	3
Inkef	3
Aglaia BioMedical Ventures	3
Inserm Transfert Initiative	3

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Zürcher Kantonalbank is an independent, incorporated public-law institution is its public service mandate. Enshrined in law, it governs the bank's economic, social, and environmental commitment.

Investment focus

Health Care, Medical Device, Biotechnology
Seed, Series A, Funding Round
Switzerland, Japan, Spain

Portfolio highlights

askEarth — We are your experts in satellite imagery (Earth Observation) and large language models (LLMs)
EarlySight — EarlySight start-up company is founded in order to accelerate the development and to bring the technology to clinics.
Polypeptide Group — The PolyPeptide Group is a contract manufacturing organization for peptides and peptide related molecules. A global presence throughout the world assures our clients a reliable supply with the necessary capacity for an uninterrupted service.The Group is one of the world’s largest independent contract manufacturers of therapeutic peptides forthe cosmetic, pharmaceutical and veterinary markets employing more than 450 people in six manufacturing sites located in France, India, Scandinavia and the USA.PolyPeptide Group is privately-held organization that manufactures over one third of all approved peptide drug substances (22 of 62 approved products worldwide) accounting for over 25% of the sales of outsourced peptide therapeutics worldwide.

The Foundation for Technology Innovation gives financial assistance to creative and technological projects at various phases of development. FIT funds projects in energy and the environment, information and digital technology, life sciences and health, precision industries, and nutrition and agriculture.

Investment focus

Health Care, Biotechnology, Information Technology
Debt Financing, Grant, Seed
Switzerland, France

Portfolio highlights

INERGIO — This EPFL spin-off is developing faster, portable energy units that offer ten times the power at half the weight of current technology. Founder Mahmoud Hadad’s fuel cell innovation, which uses standard butane or propane that’s safe and available worldwide, offers high autonomy. INERGIO’s fuel cell geometry allows unlimited scaling, making thetechnology suitable for applications ranging from charging consumer electronics to auxiliary power for drones to automobile fuel cells. The team has a working prototype and is looking to have its minimal viable product by summer 2020 to start the pilot project with potential partners and customers.
Brightank — Catalyzing your Decarbonization. Brightank accelerates decarbonization with ammonia cracking catalysts, turning ammonia into fuel for heavy transport, hydrogen supply, and power. EPFL spin-off
DigeHealth — DigeHealth's approach to monitoring gut health using bowel noises and body measurements could provide some really valuable insights into digestive well-being.

BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
Switzerland, Germany, France

Portfolio highlights

ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
TOLREMO therapeutics — TOLREMO therapeutics is striving to prevent the development of cancer therapy resistance through its proprietary drug discovery and development platform. Learn more about us.
Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and

Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.

Investment focus

Health Care, Software, Biotechnology
Series A, Seed, Series B
Switzerland, France, Germany

Portfolio highlights

Q.ANT — Q.ANT develops photonic processors for AI and high-performance computing, utilizing light for information processing. The company also produces quantum sensors offering ultra-high magnetic field sensitivity in a compact form factor. These products aim to enable more intelligent and sustainable systems across various sectors like data centers,aerospace, and medical technology.
Poppins — Mila merges music, technology, and neuroscience to reshape therapy into a musical experience. We create musical games for children based on neurologic music therapy methods. These games are designed to address learning dissabilities like dyslexia, providing a digital treatment at home and helping identify these conditions. Behind these games, weleverage data science and new technologies to interpret learning, language, and motor performance into a cognitive score. Our goal is to improve the process for patients receiving treatment and to reaching the vast undiagnosed majority.
EarlySight — EarlySight start-up company is founded in order to accelerate the development and to bring the technology to clinics.

VI Partners are Venture Capitalists successfully financing outstanding teams and innovations in the Healthcare and Technology space since 20 years.

Investment focus

Health Care, Biotechnology, Medical Device
Series A, Series B, Seed
Switzerland, Germany, United States

Portfolio highlights

Kadoa — AI-Powered Web Scraping Automation | No-Code, Maintenance-Free Data Extraction & Transformation
Buynomics — buynomics is the leading solution to optimize your product portfolio. Our clients use buynomics to optimize pricing, promotions, & portfolio architecture.
Unique — Unlock the power of generative AI in Finance with Unique FinanceGPT. Get custom use cases and accurate insights in a secure, enterprise-ready platform.

Eclosion assists entrepreneurs with the necessary resources to bridge the gap between their laboratories and the stage where the start-up

Investment focus

Biotechnology, Pharmaceutical, Health Care
Seed, Series C, Funding Round
Switzerland

Portfolio highlights

KYLYS — KYLYS is an innovative Swiss company based in Geneva founded in March 2017. KYLYS provides people and patients with highly effective and safe products based on biomolecules.
Genkyotex — Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases.
MPC Therapeutics — MPC Therapeutics develops a novel class of compounds with application in Immunotherapy and Metabolic diseases

Schroders Capital provides investors with access to a broad range of private asset investment opportunities, portfolio building blocks and customised private asset strategies. With over $65 billion assets under management, we offer a diversified range of investment strategies, including real estate, private equity, secondaries, venture capital, infrastructure, securitised products and asset-based finance, insurance-linked securities and impact investing.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series C, Series A
Switzerland, United States, India

Portfolio highlights

Bizongo — Bizongo is a Tech-Enabled B2B Platform for Packaging, Apparels & Other Customised Goods. We digitally transform vendor management & supply chain.
Lenskart — Lenskart, the first of its kind online optical store in India, has made it possible to acquire a good quality pair of specs with prescription lenses for just Rs. 399, all this while you sit in the comfort of your home. With a 48-hour free home delivery guarantee and 365 days return policy, Lenskart.com is doing what e-commerce hasn’t been able todo in India yet.The website has over 500 designs of eye frames, in multiple colors, for all age groups, from Rs. 399 all the way to Rs. 4,000 for a pair. All one needs to do is select a frame, fill in their power, and place an order. You can pay online or at the time of delivery.Lenskart.com has the biggest collection of discounted contact lenses consisting of all top-notch brands (viz. Johnson & Johnson, Bausch & Lomb, Ciba Vision are to name a few) and be it disposable, toric, colored or bifocal contact lenses, you can find all possible types here. Lenskart is dedicated to providing its customers with a simple, hassle-free way to replace their contact lenses. One can receive the exact same contact lens, their doctor prescribed, delivered to their door, at a great price.
Memo Therapeutics — Memo Therapeutics AG translate immune responses into superior medicines. Our best-in-class antibodies transform lives of patients with viral infections & cancer

redalpine is a thesis-driven vc with deep expertise in software and science. since 2006. we believe in the power of big ideas and in empowering game changers. we don't just invest, we co-create a better tomorrow. together with you.

Investment focus

Biotechnology, Software, Health Care
Series A, Seed, Series B
Germany, Switzerland, United Kingdom

Portfolio highlights

voize — voize is an app for care documentation via voice input.
DejaBlue — DejaBlue delivers a smart EV charging platform that supports solar integration, reduces energy costs, and improves site operations. Easily connect chargers, manage your fleet, and optimize performance with reliable tools built for scale.
Lyceum — Introducing the smartest way to train your models in the cloud. The electricity socket for your infrastructure needs.

Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

Rhygaze — Rhygaze develops a novel gene therapy that targets cone cells to restore vision in patients suffering from diseases causing blindness.
Granite Bio — Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
Atalanta Therapeutics — Atalanta was created to address the urgent global need for interventions to treat neurodegenerative diseases.

Providing capital plus strategic, clinical, operational, financial, and commercial support to deliver the added value inventors seek.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, The Netherlands, Switzerland

Portfolio highlights

Cyted — Cyted focuses on providing digital diagnostic infrastructure to drive the earlier detection of disease. Our technologies use AI and novel biomarkers to improve patient outcomes.
Perfuze — Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. Perfuze is located within Galway City in the West of Ireland. The founders have over 30 years combined medtech experience within start-up and large corporations.Perfuze is developing innovative medical technology to treat acute ischemic stroke.Perfuze is developing innovative cathetertechnology to treat acute ischemic stroke. Their technology is intended to provide superior clinical outcomes in shorter procedural times; resulting in safe, cost-effective therapy. Perfuze was founded in 2018 by Wayne Allen and Liam Mullins. The founders have over 30 years combined medtech experience within start-up and large corporations. Perfuze is currently located in the Business Innovation Centre on the campus of the National University of Ireland, Galway, and is in the process of relocating to the IDA Business Park in Dangan, Galway.
Avidicure — Avidicure is developing dual agonistic avidity-engineered multifunctional antibodies, AVC-Boosters, as monotherapy for treatment of cancer

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, United Kingdom, Switzerland

Portfolio highlights

Biolinq — Introducing a revolutionary platform for metabolic health.
ChEmpower — ChEmpower is an advanced materials company that develops chemically reactive, abrasive-free planarization pads to improve chip yields and sustainability in semiconductor manufacturing.
Corvic AI — Corvic AI is pioneering a new era of Data-Centric AI Cognitive Infrastructure by transforming raw enterprise data into AI-ready intelligence.

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
France, United States, United Kingdom

Portfolio highlights

Actithera — Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows.
One Biosciences — One Biosciences unlocks routine analysis of tumor heterogeneity through AI-powered single-cell technologies, transforming precision medicine.
Galvanize Therapeutics — Galvanize Therapeutics is an energy-based medical device technology that provides therapeutic products and services to deliver healthcare solutions. The company aims to become the global leader in delivering medical technology innovations that drive biological processes to treat a range of diseases, starting with treating chronic bronchitissymptoms, cardiac arrhythmias, and solid tumors.It was formed by Apple Tree Partners in 2022.

Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Switzerland, Canada

Portfolio highlights

Granite Bio — Targeting fundamentals of Inflammation, Autoimmunity and Fibrosis. Granite Bio develops first-in-class therapeutic antibodies depleting pathogenic cells with the potential to transform inflammatory and fibrotic diseases.
Helicore Biopharma — Helicore Biopharma is at the forefront of developing cutting-edge treatments for obesity and related disorders.
Kriya Therapeutics — Kriya is a biopharmaceutical company developing gene therapy to address common diseases that impact millions of people worldwide. Learn more.

GoBeyond is a FinTech company transforming angel investing into a new scalable asset class for small and large, novice to experienced investors. It offers a unique deal platform, portfolio tools, syndication/pooling, due diligence, investment monitoring services, training and certified deal leaders.Its clients are individuals, familyoffices, professional groups and corporations. It is active in the EU, Switzerland and the US. GoBeyond also offers educational training modules for angel investors in 11 categories.

Investment focus

Information Technology, Medical, Software
Funding Round, Seed, Series A
Switzerland, Germany, United Kingdom

Portfolio highlights

LEND — LEND provides peer to peer lending in Switzerland. It connects investors with borrowers. Moreover, investors earn substantial returns and borrowers benefit from low interest rates. The company is based in Switzerland and it was founded in 2015.
AVAtronics — AVA Active Noise Cancellation (ANC) Solution is a breakthrough in Audio Industry. AVA is the first and only TRUE WIDE-BAND ANC in the market capable of selectively cancelling all annoying noises we want to get rid of without compromising the quality of Music or speech.
Blumer — Blumer is a social networking platform that provides social networks that can monetize time by consuming advertisements, selling nfts, and making crypto transactions. It offers social networks, crypto, digital marketing, and blockchain.

High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.

Investment focus

Software, Biotechnology, Information Technology
Seed, Series A, Funding Round
Germany, Switzerland, United States

Portfolio highlights

Mevaldi — Mevaldi is a biotechnology company. They investigate, select, and bring to market new technologies in the field of bio-based chemicals. They provide a revolutionary approach that integrates the large-scale biological conversion of sugars to low-cost mevalonolactone with a further cascade of thermo-catalytic conversions to various bio-monomers.
TrustNXT — TrustNXT is the trust authority for digital media, providing innovative software solutions to safeguard digital photos and videos from manipulation. Our technology verifies the origin, content, and metadata of digital media, while advanced forensic tools empower users to assess the trustworthiness of visual content. With a mission to protectauthenticity and foster safer digital environments, TrustNXT is committed to combating fraud and ensuring the integrity of digital media in today's digital world.
Pactos — Pactos streamlines and digitizes processes to enable large and medium-sized businesses to effectively and centrally procure and manage their contingent labor.

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
United States, Denmark, United Kingdom

Portfolio highlights

Mission Bio — We offer the only multi-omics single-cell technology solution that simultaneously detects SNV, CNV, and protein data from the same cell. Find out more.
Sparrow Quantum — Sparrow Quantum, a global leader in quantum photonic chip technology. Explore innovative solutions driving advancements in quantum computing, communication, and beyond. Stay ahead with cutting-edge technologies shaping the future.
Reunion Neuroscience — Reunion Neuroscience is a clinical-stage pharmaceutical company developing therapeutic solutions for underserved mental health conditions. The Company’s lead asset, RE104, is a proprietary, novel serotonergic psychedelic compound being developed as a potential fast-acting and durable antidepressant for patients suffering from postpartum depressionand other mental health conditions. Reunion is also developing the RE200 series, which includes compounds with the potential for more selective serotonin receptor activity and reduced psychoactivity for application in more chronic treatment paradigms and indications.

Kinled was founded in 1980 to retain the investment assets of the Aisher family.In 1990, the investment focus shifted to a portfolio of early stage investments applying Kinled’s company development experience alongside the endurance and passion of family owned investments together with the strategic focus of venture capitalists.Since then,Kinled has taken 8 companies to public markets and many more to successful trade sales at significant multiples.

Investment focus

Biotechnology, Health Care, Financial Services
Seed, Funding Round, Series A
United Kingdom, United States, Switzerland

Portfolio highlights

Xapien — Xapien delivers automated insight reports on companies and individuals in minutes, so you can make informed business decisions quickly and with confidence.
OneTrust — OneTrust is a provider of privacy management and marketing compliance technology that helps organizations comply with global regulations. It automates privacy impact assessments and data inventory mapping, enforces risk remediation actions, and triggers recurring audits for continuous compliance monitoring across customer, employee, and vendor datatransfers. Its web-based software can be accessed on any device and provides a single place for a private office to collaborate with business groups, vendors, and trusted advisors managing privacy risks. The result is the ability to demonstrate privacy by design and ongoing compliance with policies, data privacy laws (GDPR, BCR, Privacy Shield), and other privacy frameworks (HITECH, ISO, GAPP, APEC).The company was founded in 2016 and is headquartered in Atlanta, Georgia.
Connect Earth — Connect Earth is an environmental data company that builds the infrastructure for climate-conscious products by aggregating and standardising environmental data and making it available through developer-first toolkits. The core product is an API solution that calculates the carbon impact of spend-based financial transactions of consumers and companies.

Index Ventures is an international venture capital firm with dual headquarters in San Francisco and London, investing in technology-enabled companies with a focus on e-commerce, fintech, mobility, gaming, infrastructure/AI, and security.

Investment focus

Software, E-Commerce, Internet
Series A, Series B, Seed
United States, United Kingdom, France

Portfolio highlights

Spiko — Spiko is a tokenization platform that offers to be the supplier of tokenized Money Market Funds.
Mistral AI — Take control of the future with a complete AI solution from platform to interface, with open, customizable models that can be deployed anywhere.
Parallel — Parallel is a technology company focused on adapting the web for artificial intelligences. It builds retrieval, ranking, and reasoning systems that enable AIs to perform high-value tasks using web data. The company's initial offering is an API designed to facilitate these interactions, enhancing the capabilities of advanced AIs.

Bernina BioInvest is an investment Firm.

Investment focus

Biotechnology, Health Care, Biopharma
Seed, Series A, Series B
Switzerland

Portfolio highlights

HAYA Therapeutics — Pioneering next-generation therapies for fibrotic diseases. Learn more about our approach here.
Memo Therapeutics — Memo Therapeutics AG translate immune responses into superior medicines. Our best-in-class antibodies transform lives of patients with viral infections & cancer
Synendos Therapeutics — Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.

We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, Switzerland, United Kingdom

Portfolio highlights

Windward Bio — Windward Bio is a clinical-stage, drug development company committed to improving outcomes for people living with advanced immunological diseases.
Alleviant Medical — Interventional therapy for congestive heart failure
Callio Therapeutics — Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits.

Boosting health pioneers. We invest in early stage start-ups in different sectors: medtech, life science, biotech, mental health, public health, well-being.

Investment focus

Medical, Health Care, Biotechnology
Seed, Series A
Switzerland

Portfolio highlights

Testmate Health — 2 in 1 urine test with immediate results for Chlamydia trachomatis and Neisseria gonorrhoeae. Results within minutes & 100% anonymous.
Limula — Limula provides a unique platform technology enabling scale out of cell therapy production. By bringing manufacturing closer to the patients, our solution will broaden access to these highly personalised treatments. Our patented solution is composed of an automation unit and single use kits, allowing healthcare providers to safely manufacture CGTin a decentralized manner. We support companies at all stages of the cell therapy life cycle, from R&D to routine production.
SEITO Biologics — SEITO Biologics AG develops innovative IL-2 immunotherapies that preferentially activate T regulatory (Treg) cells, while sparing cytotoxic effector immune cells.

4FO Ventures

Investment focus

Artificial Intelligence, Health Care, Medical
Series A, Seed, Series B
Switzerland

Portfolio highlights

Positrigo — NeuroLF is an ultra-compact brain Positron Emission Tomography system. Our technology makes functional imaging accessible for people worldwide.
Ecorobotix — ecoRobotix contributes to an agriculture that respects the environment, focusing on soil and hydrological resources conservation and using a minimum amount of energy. ecoRobotix aims to offer precise, safe, reliable and affordable robotic solutions that simplify farmers’ life to produce healthy food. In particular, its revolutionary solar-poweredweeding robot offers a more sustainable use of herbicides while reducing farmers costs.
ARTIRIA Medical — Artiria Medical empowers catheters and guidewires. We develop cutting edge technologies to revolutionize the limits of neurointerventional procedures, enabling a seamless navigation and stroke treatment.

Swisscom Ventures is an venture capital arm of Swisscom AG, that specializes in early stage tech investments founded in 2007.Swisscom Ventures invests in growth companies with emerging business models and technologies of strategic relevance to Swisscom's core business. As a value-add investor, Swisscom brings its investees the technicalexpertise and strategic insights of an incumbent telecom operator. We act as a bridge to Swisscom's operational business units, which portfolio companies can also leverage as a test environment for their products and services.Swisscom Ventures seeks minority stakes in companies related to the information/communications/entertainment space.

Investment focus

Software, SaaS, Information Technology
Funding Round, Series B, Series A
Switzerland, United States, United Kingdom

Portfolio highlights

ANYbotics — ANYbotics provides autonomous legged robots for industrial applications to provide high availability and reliability in automated routine inspections.
Lumotive — Lumotive is a Seattle-based startup company developing high performance, solid-state lidar for autonomous systems in the automotive, UAV, robotics and related industries. The company's revolutionary beam-steering technology leverages Liquid Crystal Metasurfaces (or LCMs) implemented in mature semiconductor manufacturing processes to deliversmall, inexpensive 3D perception systems with unprecedented performance and reliability. For more information, visit us at www.lumotive.com.
RTDT Laboratories — Make real-time decisions to optimise fleet operation through unique structural health insights

Venture capital for companies developing innovative therapeutics.

Investment focus

Biotechnology, Therapeutics, Health Care
Series A, Series C, Seed
Switzerland, France, The Netherlands

Portfolio highlights

Citryll — Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes that enable doctors to help in the treatment of lupus,vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis.Citryll was established in 2015 and is headquartered in Oss, The Netherlands.
Vico Therapeutics — Pioneering RNA-based science to target the root cause of rare genetic neurological diseases VO659: The first clinical candidate directly targeting the CAG repea
Callio Therapeutics — Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits.

Fongit Seed Invest (FSI) is the leading Seed Money Fund of Switzerland for young technology companies. It provides smart seed capital.

Investment focus

Health Care, Medical, Biotechnology
Seed, Series A, Series B
Switzerland

Portfolio highlights

EBAMed — EBAMed SA is a Swiss startup based in Geneva whose mission is to enable safe and effective non-invasive treatments of heart arrhythmias with protontherapy. The company is currently developing a medical device to enable non-invasive heart motion imaging and real-time synchronization of the therapeutic beam. This device consists in both hardware andsoftware components and expands treatment possibilities for existing protontherapy centres, enabling them for the first time to treat heart patients.
Gmelius — Gmelius is the world's first 360 email collaboration platform designed for Gmail and your company's daily apps. Join the async movement!
Annaida Technologies — Annaida Technologies has developed a groundbreaking device, EmbryoSpin, that performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies.

Penny Schiffer - CEO & Co-founder @ Raized.ai

Investment focus

Health Care, Medical, Finance
Funding Round, Seed, Series A
Switzerland, Germany, United Kingdom

Portfolio highlights

Versameb — Versameb AG is a preclinical-stage biopharmaceutical company located in Basel, Switzerland managed by an experienced scientific and business pharmaceutical industry team. The company’s focus is the development of novel RNA-based therapeutics. Versameb’s proprietary VERSagile technology platform enables efficient development of functional mRNAmolecules for customized protein expression and modification in multiple disease areas with high unmet medical need.
Enterprise Bot — Cost-effective Conversational AI solutions transforming customer interaction for global enterprises. Discover cutting-edge chat, email, and voice tech.
Scientific Visual — Scientific Visual supplies quality control workstations to visualize defects in non-polished sapphire such as watch covers, ingots and wafers.

Foundational partners to ambitious founders at every stage of company-building.

Investment focus

Software, Health Care, Biotechnology
Series A, Series B, Series C
United States, India, Canada

Portfolio highlights

Aurelian — Aurelian is an AI platform designed to automate routes, triage, and resolve non-emergency police calls.
Mojo Vision — Mojo Vision is a developer of augmented reality products and platforms intended to invent the future of computing. The company has developed a smart contact lens with a built-in display that gives timely information without interrupting the focus and delivers immediate, powerful, and relevant information without the intrusions of today'smobile devices, enabling users to connect with others at a glance, anytime, anywhere handsfree.Mojo Vision was founded in 2015 and headquartered in Saratoga, California.
Strive Health — Strive Health is a built-for-purpose company working with innovative payors and providers to transform kidney care. Strive Health significantly improves patient outcomes and experience with a high-touch, technology-enabled clinical model that cares for chronic kidney disease patients across their entire healthcare journey, from primary care-levelengagement through dialysis. Strive was launched out of Oxeon’s Venture Studio and is backed by New Enterprise Associates, Town Hall Ventures, Echo Health Ventures, and Ascension Ventures.

Endeavour Vision is an investment advisory firm focused on transformative healthcare technologies.

Investment focus

Health Care, Medical, Biotechnology
Series C, Series B, Series A
United States, Switzerland, France

Portfolio highlights

Gynesonics — Gynesonics is a women’s healthcare company focused on the development of advanced incision-free solutions for the treatment of uterine conditions. Gynesonics serves customers worldwide. It was founded in 2005 and is headquartered in Redwood City, California.
Nalu Medical — Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people.The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS)and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California.
Kestra Medical Technologies, Inc. — Kestra Medical Technologies is a wearable medical device and digital healthcare company that protects patients with diagnostic and therapeutic technologies that are intuitive, and mobile. They provide intuitive medical technologies to protect and support at-risk patients.

BB BIOTECH VENTURES is a healthcare-dedicated venture capital fund, focused on companies that develop and market drugs and medical devices. The Guernseyâ€“based fund is advised by the Bellevue Asset Management Group, which has operations in CuraÃ§ao, Boston/USA and Kusnacht/Zurich, Switzerland. BB BIOTECH VENTURES has a dedicated teamof investment advisors and an advisory board. In addition, it is supported by all of the Groupâ€™s health care investment experts, and an extensive network of specialists and advisors. Our goal is to maximize the returns to our investors. To achieve this goal, we combine hard working, experience, networking, and focus on value creation.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Series C, Series A, Funding Round
United States, Switzerland, Italy

Portfolio highlights

Arvinas — Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins.
AM Pharma — AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derivedpeptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.
Molecular Templates — Molecular Templates is a clinical-stage biopharmaceutical company developing engineered toxin bodies (ETBs) for the treatment of cancers.

Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series C, Series A
United States, The Netherlands, Germany

Portfolio highlights

Splice Bio — Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
Spyglass Pharma — Spyglass Pharma focuses on the development of novel treatments for chronic ophthalmic diseases based on technology. The company designs to deliver multiple drugs to address additional ophthalmic indications.
MicroTransponder — MicroTransponder is a medical device company that develops and commercializes neurostimulation devices to treat neurological diseases. Its therapies include paired vagus nerve stimulation system (Paired VNS System) and wireless neurostimulation system for the treatment of chronic pain, post-stroke upper limb mobility issues, and variousneurological indications that enable healthcare practitioners to treat post-stroke upper limb mobility issues.Founded in 2007, MicroTransponder is headquartered in Dallas, Texas.

NeoMed Management is an international venture capital investment firm, exclusively focused on the healthcare industry. Founded in 1997, NeoMed has established five funds to date.NeoMed invests in emerging companies with outstanding growth prospects. These companies are developing innovative and proprietary medical products that addresssubstantial market opportunities in the pharmaceutical, medical device and diagnostics industries.NeoMed has a multi-stage investment approach and invests at all stages of development from start-up to later stage growth financings. Since inception, NeoMed has successfully invested in more than 30 companies in Europe, including Scandinavia, Switzerland, Germany and the UK, and in North America.From offices in Norway and Switzerland, NeoMed’s experienced investment team works closely with its entrepreneurs and a broader industry network to support the growth of its portfolio companies.NeoMed is currently focusing on NeoMed Innovation IV L.P. and NeoMed Innovation V L.P.

Investment focus

Health Care, Biotechnology, Medical
Series B, Series C, Funding Round
Switzerland, United States, Italy

Portfolio highlights

Sonendo — Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely usedendodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.
Oxular — Oxular is a clinical-stage retinal therapeutics company that is developing technology to transform the treatment of retinal disease, offering patients life-changing solutions to their unmet needs.
JenaValve Technology — Redefining what it means to treat patients with severe aortic regurgitation.

Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Series C
United States, China, Israel

Portfolio highlights

CHARM Therapeutics — CHARM Therapeutics uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins.
Treeline Biosciences — Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions. The company was founded in 2021 and is headquartered in Stamford, CT.
Congruence Therapeutics — ABOUT US We are a drug discovery company that is uniquely harnessing the power of protein dynamics, biophysics, machine learning and computational chemistry. Our Science Traditional drug design is limited At Congruence,

Aravis is the first independent Swiss on-shore private equity house, an established investor in the renewable energy and life science spaces. We are a "hands-on" investor taking leading positions and understanding the balance between finance, commercial assets and people. With this distinct and crafted approach, we are serving over 30leading investors including corporates, pension funds, government funds, insurance companies and family offices. Currently actively managing more than a quarter of a billion Swiss francs, we have a cumulative history of investments in over 100 companies. These have resulted in several noticeable exits including the divestment of several renewable energy companies and a number of life science reverse take-overs, listings and trade sales. Our many years of experience in the Swiss fund industry have enabled us to establish a platform with a comprehensive offering of investment, accounting, regulatory and reporting expertise. Located in Zurich, Aravis was founded in 2001.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
Switzerland, United States, Denmark

Portfolio highlights

Bird Rock Bio — We are a biopharmaceutical company focused on the development of proprietary cannabinoid derivatives for the treatment of glaucoma and other diseases with significant unmet medical needs. Our innovative approach to drug development combines strong science with the drive to find solutions where the need is the greatest.
Synaffix BV — Synaffix BV is a clinical-stage, Netherlands-based biotech company that has established a proprietary antibody-drug conjugate (ADC) technology platform that enhances efficacy and tolerability compared to all 3 major clinical-stage ADC technologies. We have a 'one-stop' technology offering (including 4 different ADC payloads) thatenables the development of proprietary ADCs from any antibody and our patent portfolio provides patent protection of resulting Products through at least 2035.Our business model is technology out-licensing and we regularly engage in research collaborations with other companies that are interested in developing highly competitive ADC products for their own pipelines.Disclosed partnerships to date include those with ADC Therapeutics and Mersana Therapeutics
Hedera-22 — Hedera-22 expanded its scope to include the identification of natural products through the use of in-house bio-informatic prediction technologies.

Founderful operates as a venture capital firm and a Switzerland’s leading pre-seed fund.

Investment focus

Software, Artificial Intelligence, Information Technology
Pre-Seed, Seed, Series A
Switzerland, United Kingdom, Canada

Portfolio highlights

Oxyle — Permanently eliminate PFAS from your wastewater. Book a pilot and lead the way to clean, safe waters.
Zuriq — Thoughts, stories and ideas.
Kyan Health — Kyan Health is the first Swiss digital health company to provide end-to-end, fully personalized, evidence-based mental wellbeing and health solutions for employees and their families. The company's mission is to create a frictionless experience when accessing and engaging with mental health and wellbeing support services at work – fromemployee engagement and awareness creation over self-improvement and self-care to coaching and counseling.

Swiss ICT Investor Club (SICTIC) connects smart money investors to Swiss seed and early-stage tech startups.

Investment focus

Software, Artificial Intelligence, Information Technology
Seed, Pre-Seed, Funding Round
Switzerland, Germany, United Kingdom

Portfolio highlights

Nextesy — Nextesy is a pioneering start-up that uses AI to simplify and automate important business processes, allowing businesses to alleviate the strain of repetitive manual procedures while increasing operational efficiency and scalability.
Scanvio — Scanvio Medical provides gynecologists, endometriosis centers and ultrasound manufacturers with an AI-guided ultrasound software for faster endometriosis diagnosis.
Insurteam — Insurteam provides the benefits of its technology to all insurance companies that service the travel and leisure sector.

Aargauische Kantonalbank (AKB) is a classical universal bank for private and corporate clients and institutional investors. They offer comprehensive services in all areas of banking. Their strengths include the needs-based, personalized and comprehensive advice and a comprehensive and competent care. The AKB has 31 offices in the canton of Aargauand the adjacent area Solothurn Olten-Gösgen-Gäu. Their company has about 790 employees and about 79 students. They serve approximately 230,000 customers. The AKB has been awarded by the rating agency Standard & Poor's AA + rating.

Investment focus

Medical Device, Dental, Biotechnology
Series B, Series A, Seed
Switzerland

Portfolio highlights

Peripal — Introduction to Peripal and what we do. Peripal AG manufactures and distributes the patient assist device PeriSafe to allow more patients to perform peritoneal dialysis at home.
InterAx Biotech Ltd — InterAx Biotech integrates experimental and computational pharmacology to reveal critical properties of novel GPCR drug candidates. Work with us now!
ELDICO Scientific — ","image":"","link":"","status":"disabled","title":""}},{"type":"grid_item","props":{"content":"Join our next webinar\nDiscover how electron diffraction was pivotal to provide the structure of biogenic crystals\nPresented by: Dr. Benjamin Palmer, Ben-Gurion University","status":"disabled","title":""}},{"type":"grid_item","props":{"content":"\n","status":"disabled"}}]},{"type":"image","props":{"block_align":"right","image":"wp-content\/uploads\/2024\/04\/ELDICO-Linkedin-page-v1.png","image_svg_color":"emphasis","image_svg_inline":false,"image_width":"150","link":"https:\/\/www.linkedin.com\/company\/19160028\/admin\/feed\/posts\/","link_target":"blank","margin":"small","margin_remove_bottom":true,"margin_remove_top":true,"maxwidth":"medium","maxwidth_breakpoint":"s","position":"relative","position_left":"150","position_top":"0","status":""}}]}]},{"type":"row","children":[{"type":"column","props":{"image_position":"center-center","media_overlay_gradient":"","position_sticky_breakpoint":"m"},"children":[{"type":"slideshow","props":{"class":"home_header","content_margin":"small","css":".el-overlay {\n\tbackground: rgba(255,255,255,0.7);\n\tpadding: 15px 20px;\n\tbox-shadow: 10px 10px 0 0 rgba(0,0,0,0.3);\n}\n.el-image {\n\tbackground-position: top center;\n}","link_style":"primary","link_text":"Read more","margin":"medium","margin_remove_bottom":true,"margin_remove_top":true,"meta_align":"below-title","meta_element":"div","meta_style":"text-meta","nav":"","nav_align":"center","nav_breakpoint":"s","nav_color":"","nav_margin":"","nav_position":"bottom-center","nav_position_margin":"medium","overlay_animation":"parallax","overlay_container":"","overlay_container_padding":"","overlay_position":"bottom-left","overlay_style":"overlay-default","overlay_width":"","position":"relative","position_top":"0","show_content":true,"show_link":true,"show_meta":true,"show_thumbnail":true,"show_title":true,"slidenav":"center-right","slidenav_breakpoint":"s","slidenav_hover":false,"slidenav_large":false,"slidenav_margin":"large","slidenav_outside_breakpoint":"xl","slidenav_outside_color":"","slideshow_animation":"fade","slideshow_autoplay":true,"slideshow_autoplay_interval":"12","slideshow_autoplay_pause":true,"slideshow_box_decoration":"","slideshow_box_shadow":"","slideshow_height":"section","slideshow_kenburns":"","slideshow_max_height":"","slideshow_min_height":"200","status":"","thumbnav_height":"75","thumbnav_svg_color":"emphasis","thumbnav_width":"100","title_element":"h1","title_style":"h3"},"children":[{"type":"slideshow_item","props":{"content":"Electron Diffraction (ED) is gaining momentum in science and industry. The application of ED for performing nano-crystallography is a disruptive innovation

Initiative Capital Romandie is a private equity fund that focuses on technology companies based in Western Switzerland.

Investment focus

Health Care, Biotechnology, Medical Device
Series A, Series B, Series E
Switzerland

Portfolio highlights

PicoDRILL — PicoDRILL generates technology leadership for its partner/customers through cutting-edge technology for drilling needs in the nanotechnology field. picoDrill is a private company located in Lausanne, Switzerland.
Diagnoplex — Diagnoplex has been founded in 2005 supported by seed financing fron the Novartis Forschungsstiftung, Swiss Confederation CTI project, Canton de Vaud FIT and the Gebert RÃ¼f Stiftung. The company has performed a 140 patient prospective pilot study demonstrating technical and clinical feasibility of its colorectal cancer screening test COLOX as wellas its high sensitivity and specificity.
Aleva Neurotherapeutics — Aleva Neurotherapeutics develops the next generations of implantable Deep Brain Stimulation systems, based on a MEMS technology. Our unique microfabricated devices enable Target Specific Stimulation and optimization of current therapies. They will also permit targeting new areas of the brain and the measurement of neurophysiological activity,translating into faster, more certain surgical placement of electrode leads. The first application will be in Deep Brain Stimulation for indications such as Parkinson's Disease and Essential Tremor.To maximize the value it can capture from its technology, Aleva intends to develop a series of two therapeutic products, while eliminating technological and clinical development risks at each stage.Our first product, directSTIM, an intelligent directional electrode connected to a best-in-class Deep Brain Stimulation system, has successfully completed an acute clinical trial at the Inselspital in Bern, Switzerland. It is currently further developped for a long term use.Aleva has been was founded in 2008 in Lausanne, Switzerland. It has raised 42 MUSD to date from prominent VCs, private investors and a strategic investor. The company is ISO13485 certified.

Polytech Ventures are an early stage VC firm based in Switzerland with a strong international focus. Their strategic location at EPFL in Lausanne grants us access to one of the most dynamic and recognized innovation centers in the world

Investment focus

Financial Services, FinTech, Software
Seed, Series A, Funding Round
Switzerland, United States, Spain

Portfolio highlights

yamo — Frische Bio-Kindernahrung von yamo, so lecker wie selbstgemacht und kostenlos direkt zu dir nach Hause geliefert. Jetzt probieren und profitieren.
Relai — All you need to get started is to download our award winning Relai app, complete a simple verification and start buying with as little as 50 CHF/EUR.
Earny — Payroll management built for Startups & SMEs. Swiss payroll service with no hidden fees & no hassle

An international, Swiss-based family office, focusing on private equity (venture & buy-out), real estate and listed assets.

Investment focus

Health Care, Software, Biotechnology
Series A, Seed, Funding Round
France, Germany, Switzerland

Portfolio highlights

Mediaire — mediaire supports radiologists with AI-based tools for MRI reporting. This enables them to make a more accurate and objective assessment even faster.
Newronika — Newronika restores brain and body functions with innovative technologies. We translate our deep knowledge on biosignal decoding into clinical practice, with the aim of improving treatments, health, and wellness. With our revolutionary brain devices, the patient receives the right stimulation at the right moment, thus becoming able to perform normaldaily activities and improve quality of life. Newronika is the spin-off company of two leading research institutions in Italy, the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Hospital and the University of Milan. Newronika comprises a multidisciplinary team formed from Neuroscience research groups and involves scientists with expertise in neurophysiology, neurology, biomedical engineering, neuropsychology, bioinformatics, and biotechnologies.
Happydemics — Happydemics is the story of frustration become conviction. A frustration with the complexity of market research, neglected by decision-makers in favor of a simplistic and stereotypical vision of a target. But Happydemics is above all the conviction that they must reinvent the experience of studies for brands, but also for respondents, bydemocratizing access to the opinion of all people. Happydemics was born, and 5 years later, Their conviction is stronger every day!

Kickfund is a Venture Capital fund that systematically backs companies that successfully complete Venture Kick.

Investment focus

Renewable Energy, Biotechnology, Medical Device
Seed, Pre-Seed, Convertible Note
Switzerland

Portfolio highlights

Scanvio — Scanvio Medical provides gynecologists, endometriosis centers and ultrasound manufacturers with an AI-guided ultrasound software for faster endometriosis diagnosis.
askEarth — We are your experts in satellite imagery (Earth Observation) and large language models (LLMs)
ASTRA Therapeutics — Astra - Therapeutics

B2venture is a venture capital firm focused on early-stage investments in digital and industrial technology companies. B2venture invests EUR 100m+ per year in high-growth companies with ticket sizes from EUR 0.25m to 3.5m.

Investment focus

Software, Health Care, Artificial Intelligence
Series A, Seed, Series B
Germany, Switzerland, United Kingdom

Portfolio highlights

Kiin Bio — Accelerate drug discovery with Virtual Scientists. Unified platform integrating 100+ specialized tools into one intelligent workflow.
assemblean — assemblean goal is to construct the digital manufacturing infrastructure of the future. We want to make it possible for everyone to build physical items as readily as software.
Nautica Technologies — Nautica Technologies is developing intelligent robotic technologies for autonomous ship hull cleaning and inspection. we operate at the convergence of robots, autonomy, and data to solve important difficulties in the marine industry.

Broadview Ventures, Inc. (Broadview) was established in 2008 as a new program conceived by the Leducq family. Through Broadview, the trust will work to accelerate the development of promising technology in cardiovascular and neurovascular disease through targeted investment in and support of early stage technology ventures.The FoundationLeducq, based in Paris, France, is the beneficiary of a charitable trust. In order to further the Foundation Leducq's mission in cardiovascular and neurovascular disease, the trust has made funds available to Broadview to develop a program which will promote early state technology in these fields through investments, licensing agreements and consortium funding arrangements, as well as professional, management and consulting support.With this initiative the trust joins other leaders in the venture philanthropy movement in seeking creative solutions to the problem of what is commonly referred to as the 'translational gap', a significant component of which is a lack of funding at a critical moment in the development of new technology and science.

Investment focus

Health Care, Biotechnology, Medical Device
Series A, Seed, Series B
United States, Canada, Israel

Portfolio highlights

Aria CV — Learn about Aria CV's novel implantable medical device designed to treat pulmonary hypertension (PH). Our elegant device has no battery, pump, or electronics.
Alveron Pharma — Alveron produces drugs such as cyclodextrins, pro-coagualant cyclodextrins with a unique coagulation platform technology.
Relief Cardiovascular — Relief Cardiovascular is an inQB8 medical technologies portfolio company developing a revolutionary smart implant to decongest heart failure patients.

Pfizer Venture Investments is a corporate venture capital firm that invests in areas of current or future strategic interest to Pfizer. It aims to remain at the forefront of life science advances. It identifies and invests in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’spipeline and shape the future of its industry.

Investment focus

Biotechnology, Health Care, Therapeutics
Series B, Series A, Series C
United States, United Kingdom, Switzerland

Portfolio highlights

TRex Bio — TRexBio is a discovery stage biotechnology company leveraging cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us toidentify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis.
Normunity — We create medicines that free normal immunity to defeat cancer using proprietary platforms that uncover novel immuno-oncology mechanisms.
TRIMTECH Therapeutics — Transformative treatments for CNS and inflammatory disorders by selectively destroying disease-causing protein aggregates

Discover Boehringer Ingelheim Venture Fund. We invest in groundbreaking science to transform care. Explore our mission and join us in advancing medicine.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Germany, Belgium

Portfolio highlights

Nuevocor — Nuevocor is a preclinical-stage biopharmaceutical company focused on developing gene therapy‑based treatments that have the potential to restore cardiac function in diseased hearts.
Brainomix — Since launching as a spin-out from the University of Oxford in 2010, Brainomix has developed award-winning, AI-powered imaging biomarkers, assisting physicians across the world to make better life-saving decisions. Brainomix seminal product, e-Stroke is a collection of tools that use state-of-the-art AI algorithms to support doctors by providingreal-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to get the right treatment, in the right place, at the right time.
Aignostics — Aignostics is an AI-powered precision diagnostics focused on pathology to assist with drug development and clinical research. Its “explainable” AI overcomes the “black-box” limitations of conventional AI. Based on their patented technology for reverse-engineering the black box, they render diagnostic results explainable in the form of preciseheatmaps and image overlays. These heatmaps allow pathologists to quickly verify the results of the AI, which is crucial, as the pathologist is ultimately responsible for the diagnosis.The company was founded in 2018 and is headquartered in Berlin, Germany.

BlueOcean Ventures SA provides capital, operational and company development advisory support (mentoring, company management, divestment experience, network, negotiation support) to entrepreneurs in Switzerland. BlueOcean Ventures is based in Geneva, Switzerland.

Investment focus

Health Care, Medical, Biotechnology
Series A, Seed, Series B
Switzerland, India, France

Portfolio highlights

nPloy — Simply set your filters and get matched with your dream job! Let top employers apply for you & connect with them via chat or a video call.
CyanoGuard AG — Our award-winning cyanide testing and optimizing solution is ideal for the mining, food, and medical field. It's easy to use, digital and offers real-time data.
99RetailStreet — 99RetailStreet is an eCommerce Cloudplatform for the unorganized Retail business in the developing countries. Our ecosystem targets Retailers, Distributors, and Manufacturers. 99RetailStreet provides POS solutions to Retailers, Real-Time Analytics to Manufacturers and Distributors

EVA is sparring partner for new entrepreneurs in the Life Sciences with planned base in north-western SwitzerlandThey support start-ups by helping to bridge the gap between their business idea and the successful commercialization of their life sciences projects, innovations and technologies.They provide thorough coaching and activelyencourage contact with their wide-ranging network of experts and investors as well as providing seed-phase investments.In science and technology transfer, they act as the link between researchers, universities’ scientific liaison offices, potential investors and the market.

Investment focus

Biotechnology, Medical Device, Medical
Seed, Series A
Switzerland

Portfolio highlights

AOT - Advanced Osteotomy Tools — AOT AG is a privately owned Swiss Robotic Surgery company, which spun out of the University Hospital and the University Basel (Switzerland) in 2011 and was first funded in 2012. The company is dedicated to the development, manufacturing and sales of medical devices for osteotomy pursuing the vision of contact-free bone surgery using laser,robotics and navigation systems to re-invent bone surgery (osteotomy).
POLYNEURON — Polyneuron is a developer of novel therapeutics intended to facilitate the treatment of antibody-mediated autoimmune diseases. The company's biodegradable glycopolymers-based therapeutics selectively eliminate the pathological autoantibodies, while leaving the rest of the immune system intact, enabling medical practitioners to treat patientswith immune disorders in a safe and effective manner.
Memo Therapeutics — Memo Therapeutics AG translate immune responses into superior medicines. Our best-in-class antibodies transform lives of patients with viral infections & cancer

Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.

Investment focus

Biotechnology, Health Care, Medical
Funding Round, Series B, Series A
Denmark, Sweden, Switzerland

Portfolio highlights

Kynexis — Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS). Explore our innovative approach and our dedication to improving the lives of millions globally.
Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.

SVB - Europe's biggest online shop for boating equipment and accessories! Worldwide delivery, even directly on-board!

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
The Netherlands, United States, Germany

Portfolio highlights

Onward — Working to restore movement, independence, and health in people with spinal cord injury.
Draupnir Bio — Draupnir Bio is developing new innovative therapies for patients.
Provable Markets — A comprehensive suite of trading & trade management solutions for the front, middle, and back office

Aglaia is founded on the principle that the willingness to take risks on the very early stage ventures of today results in opportunities that may grow into the winning companies of tomorrow. As such, we are typically the first provider of capital for startup and early stage companies and a driving force behind product development. Since thenumber of technological discoveries in the biomedical field is growing fast, specialized knowledge regarding the translation of these discoveries into novel products is a prerequisite for success. Aglaia's focus on oncology is considered to be a differentiating asset. We invest in novel tools and technologies as well as components of contemporary drug development.Opportunities may be derived from research centers as well as from corporate spinouts. We select, develop and commercialize promising technologies up to a level where the technology becomes attractive to larger investors or pharmaceutical and biotech companies.

Investment focus

Biotechnology, Therapeutics, Pharmaceutical
Series A, Series B, Seed
The Netherlands, United States, Switzerland

Portfolio highlights

Inthera Bioscience — Inthera Bioscience is a Switzerland-based private biopharmaceutical company developing targeted small molecule therapies for solid tumors. It is focused on developing inhibitors of intracellular protein-protein interactions employing a proprietary technology platform. The company is headquartered in Zürich, Switzerland.
InteRNA Technologies — A Dutch clinical-stage biotech company InteRNA Technologies is a Dutch clinical-stage biotech company developing a pipeline of proprietary RNA therapeutics targeting key processes in initiation and progression of human diseases, with a focus on cancer. Selected through its leading microRNA (miRNA) discovery and functional validation technology platform and enabled with a 3rd-generation drug delivery
Sapreme Technologies — Enabling endosomal escape

Inserm Transfert Initiative is a seed stage life science vehicle currently managing about â‚¬4.2M for the financing of new biotech companies. Inserm Transfert Initiative is the new investment vehicle of INSERM in France.

Investment focus

Biotechnology, Medical, Health Care
Series A, Series B, Seed
France, Switzerland, United States

Portfolio highlights

Eyevensys — Eyevensys is a address critical unmet needs in ophthalmology by providing a much better way of delivering ophthalmic drugs that overcomes the limitations of current options, such as intravitreal injections, surgery, intravitreal implants and biodegradable formulations. All of these current options have their drawbacks, given they are invasiveprocedures. Eyevensys’ goal is not only to improve short and long term therapeutic outcomes, but also to enhance compliance, improve ocular bioavailability and tolerability.They plan to build a high value product pipeline by enabling sustained production of therapeutic proteins in the eye that will deliver improved clinical outcomes while reducing the burden of frequent intravitreal or systemic injections and other invasive procedures.
VectivBio — Explore Ironwood Pharmaceuticals' commitment to GI health with innovative therapies, patient-focused research, and a vision to improve digestive disease treatment.
Aelis Farma — Aelis Farma is a pioneer in the development of signaling specific therapeutics that target GPCRs (and more specifically the CB1 receptor which is one of the most expressed GPCRs in the brain). GPCRs are the target of most therapeutic drugs. This family of receptors has the characteristics to activate several and often opposing signaling pathways.Unfortunately, most of the drugs acting on GPCRs either block or stimulate the entire signaling activity of the receptor resulting in unwanted and sometimes unacceptable side effects.

Investors by industry

Artificial intelligence

Climate

Consumer

Community